₹ 3.2 Cr
Volume Transacted
(Nov 22, 2024)
104.3 K
Stocks Traded
(Nov 22, 2024)
Last Updated on: Nov 22, 2024
The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.
1M
1Y
3Y
5Y
Date | Price (₹) | Day Open (₹) | Day High (₹) | Day Low (₹) |
---|
22 Nov 2024 | 308.55 | 311.45 | 319 | 306.65 |
21 Nov 2024 | 309 | 300.05 | 310 | 297.25 |
19 Nov 2024 | 305.85 | 312.2 | 314.25 | 303 |
18 Nov 2024 | 309.3 | 312.8 | 316 | 303.95 |
14 Nov 2024 | 307.35 | 307.95 | 324.9 | 304.65 |
13 Nov 2024 | 305.55 | 301 | 318 | 298.3 |
12 Nov 2024 | 300.35 | 286 | 311 | 286 |
11 Nov 2024 | 289 | 298.1 | 298.3 | 284.7 |
08 Nov 2024 | 298.6 | 302.95 | 309.8 | 293.55 |
07 Nov 2024 | 301.35 | 298.95 | 305.5 | 292.75 |
Date | Price (₹) |
---|---|
22 Nov 2024 | 308.55 |
21 Nov 2024 | 309 |
19 Nov 2024 | 305.85 |
18 Nov 2024 | 309.3 |
14 Nov 2024 | 307.35 |
13 Nov 2024 | 305.55 |
12 Nov 2024 | 300.35 |
11 Nov 2024 | 289 |
08 Nov 2024 | 298.6 |
07 Nov 2024 | 301.35 |
Marksans Pharma receives USFDA approval for Loratadine Tablets
Marksans Pharma announced the final approval of the Company's Abbreviated New Drug Applica...
22 Nov 202412:47
Marksans Pharma gains after receiving final nod for Loratadine Tablets from USFDA
The said drugs are indicated for the treatment of allergic rhinitis caused by pollen and u...
22 Nov 202413:23
Marksans Pharma gains after Q2 PAT rises 16% YoY to Rs 97 cr
The firm stated that growth was witnessed across all key markets, led by US and followed b...
12 Nov 202413:22
Marksans Pharma to declare Quarterly Result
Marksans Pharma will hold a meeting of the Board of Directors of the Company on 12 Novembe...
23 Oct 202417:41
Marksans Pharma announces receipt of UKMHRA approval for Fluoxetine capsules
Marksans Pharma'announced that its wholly owned subsidiary Relonchem has received Marketin...
21 Aug 202420:00
Marksans Pharma's Verna unit successfully completes USFDA inspection
Marksans Pharma announced that he USFDA has issued an Establishment Inspection Report (EIR...
20 Aug 202414:37
Unlimited trading at just
Rs. 199*